Trial site
Kuramitsu Hospital
Fukuoka, 819-0037, JapanNot linked to an institution yet
- 10running trials
- 2closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 310 trials
- Phase 22 trials
- Status
- Recruiting7 trials
- Active, not recruiting2 trials
- Completed1 trial
- Not yet recruiting1 trial
- Terminated1 trial
- Lead sponsor
- Bristol-Myers Squibb6 trials
- Eli Lilly and Company3 trials
- Ono Pharmaceutical Co., Ltd.1 trial
- Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial
- Sumitomo Pharma Co., Ltd.1 trial
Running trials
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
NCT07775300· Phase 3· Eli Lilly and Company· Source
Contact: Noriko Tamaru (principal investigator)
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· Phase 3· Bristol-Myers Squibb· Source
Contact: Noriko Tamaru, Site 1302
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· Phase 3· Bristol-Myers Squibb· Source
Contact: Noriko Tamaru, Site 0174
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· Phase 3· Bristol-Myers Squibb· Source
Contact: Noriko Tamaru, Site 0006
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732· Phase 3· Bristol-Myers Squibb· Source
Contact: Noriko Tamaru, Site 1302
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
NCT06951698· Phase 3· Bristol-Myers Squibb· Source
Contact: Noriko Tamaru, Site 0083
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
NCT06882785· Phase 3· Bristol-Myers Squibb· Source
Contact: Noriko Tamaru, Site 0008
Recruiting
A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
NCT06803823· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Contact: North America Clinical Trial Support Desk
Active, not recruiting
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
NCT06894212· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error